How’s Athenex’s Financial Performance?
In fiscal 2017, Athenex (ATNX) generated total revenues of $38 million—compared to $20.5 million in fiscal 2016.
Athenex’s Product Groups and Geographic Performance
The majority of Athenex’s revenues in Q1 2018 came from API sales, commercial product sales, and license fees.
Analyzing Athenex’s Cash Flows
In fiscal 2017, Athenex (ATNX) incurred interest expenses of $5.9 million—compared to $1.8 million in fiscal 2016.
A Focus on Pipeline Expansion Bodes Well for Athenex
Athenex announced a strategic investment of $100 million from Perceptive Advisors.
How Athenex’s Business Segments Performed in Q1 2018
Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform.
Understanding Athenex’s Research Platforms
Athenex’s (ATNX) Orascovery platform is based on the P-gp pump inhibitor molecule, HM30181A. Athenex licensed the molecule from Hanmi.
Analysts’ Ratings for Athenex and Its Peers in March
Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating.